Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression.


Journal

Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170

Informations de publication

Date de publication:
04 06 2019
Historique:
received: 06 11 2018
revised: 01 01 2019
accepted: 26 02 2019
pubmed: 2 4 2019
medline: 15 8 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

Macrophages possess intrinsic tumoricidal activity, yet tumor-associated macrophages (TAMs) rapidly adopt an alternative phenotype within the tumor microenvironment that is marked by tumor-promoting immunosuppressive and trophic functions. The mechanisms that promote such TAM polarization remain poorly understood, but once identified, they may represent important therapeutic targets to block the tumor-promoting functions of TAMs and restore their anti-tumor potential. Here, we have characterized TAMs in a mouse model of metastatic ovarian cancer. We show that ovarian cancer cells promote membrane-cholesterol efflux and depletion of lipid rafts from macrophages. Increased cholesterol efflux promoted IL-4-mediated reprogramming, including inhibition of IFNγ-induced gene expression. Genetic deletion of ABC transporters, which mediate cholesterol efflux, reverts the tumor-promoting functions of TAMs and reduces tumor progression. These studies reveal an unexpected role for membrane-cholesterol efflux in driving TAM-mediated tumor progression while pointing to a potentially novel anti-tumor therapeutic strategy.

Identifiants

pubmed: 30930171
pii: S1550-4131(19)30128-7
doi: 10.1016/j.cmet.2019.02.016
pii:
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1376-1389.e4

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/I01246X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Pieter Goossens (P)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France; Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University, 6229HX Maastricht, the Netherlands.

Juan Rodriguez-Vita (J)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France; Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.

Anders Etzerodt (A)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France; Department of Biomedicine, Aarhus University, Aarhus 8000, Denmark.

Marion Masse (M)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Olivia Rastoin (O)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Victoire Gouirand (V)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Thomas Ulas (T)

Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn 53115, Germany; PRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases and University of Bonn, Bonn 53127, Germany.

Olympia Papantonopoulou (O)

Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn 53115, Germany.

Miranda Van Eck (M)

Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Universiteit Leiden, 2300 Leiden, the Netherlands.

Nathalie Auphan-Anezin (N)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Magali Bebien (M)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Christophe Verthuy (C)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Thien Phong Vu Manh (TP)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Martin Turner (M)

Laboratory of Lymphocyte Signaling and Development, The Babraham Institute, Cambridge CB22 3AT, UK.

Marc Dalod (M)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France.

Joachim L Schultze (JL)

Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn 53115, Germany; PRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases and University of Bonn, Bonn 53127, Germany.

Toby Lawrence (T)

CNRS, Aix Marseille University, INSERM, CIML, Marseille 13009, France; Centre for Inflammation Biology and Cancer Immunology, School of Immunology & Micriboal Sciences, King's College London, London SE1 1UL, UK; Henan Key Laboratory of Immunology and Targeted Therapy, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, Henan Province, China. Electronic address: toby.lawrence@kcl.ac.uk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH